Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01179256 · ClinicalTrials.gov registry record · NA
Effect of Supplemental Oral Curcumin in Patients With Atopic Asthma
A NA study, sponsored by University of South Florida.
- Completed
- Registry status
- NA
- Development phase
- 16
- Enrollment target
NCT01179256: Completed NA study, sponsored by University of South Florida.
NCT01179256 is a NA study that has completed, run by University of South Florida. The registered enrollment target is 16 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01179256, a NA study, has completed, sponsored by University of South Florida.
- COMPLETED
- Registry status
- NA
- Development phase
- 16 participants
- Enrollment target
Study Summary
Curcumin has antioxidant properties and in animal models has numerous molecular targets, many of which are intracellular, such as transcription factors AP-1 and NF. As such, it inhibits the secretion of both pro-inflammatory (TNF-, IL-6) and anti-inflammatory (IL-10) cytokines, possibly by inhibiting transcription factors such as nuclear factor-B (NF-B) and activator protein-1 (AP-1) (Wong et al).
Interventions
- DIETARY_SUPPLEMENT CURCUMIN
- OTHER no intervention other than stopping study
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2009-03 |
| Est. Completion | 2010-03 |
| Phase | NA |
What the finished NCT01179256 record still lists
NCT01179256 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 2 interventions - of which CURCUMIN is the first listed.
NCT01179256 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01179256 about?
NCT01179256 is a clinical study titled "Effect of Supplemental Oral Curcumin in Patients With Atopic Asthma". Curcumin has antioxidant properties and in animal models has numerous molecular targets, many of which are intracellular, such as transcription factors AP-1 and NF. As such, it inhibits the secretion of both pro-inflammatory (TNF-, IL-6) and anti-inflammatory (IL-10) cytokines, possibly by inhibitin...
What is the current status of trial NCT01179256?
This trial is currently completed. It is a NA study. The enrollment target is 16 participants. The study started on 2009-03. Estimated completion is 2010-03.
What interventions are being tested in trial NCT01179256?
The interventions under investigation include: CURCUMIN (DIETARY_SUPPLEMENT), no intervention other than stopping study (OTHER).
Who is sponsoring clinical trial NCT01179256?
This trial is sponsored by University of South Florida, which has 252 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01179256's enrollment target sits among peer trials
16 1871st of 2000 higher than 120 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia